Welcome to our dedicated page for Opiant Pharmaceuticals news (Ticker: OPNT), a resource for investors and traders seeking the latest updates and insights on Opiant Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opiant Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opiant Pharmaceuticals's position in the market.
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its Q3 2020 financial results on November 12, 2020, after market close. The management team will host a conference call at 4:30 p.m. ET on the same day, accessible by dial-in and webcast. Opiant is focused on developing medications for addictions and drug overdoses, having created the NARCAN® Nasal Spray.
Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q2 2020 revenues of $6.3 million, driven by NARCAN® Nasal Spray royalties. Full-year royalty projections remain at $26.2 million. The company's cash position is strong at $30.5 million with no debt. However, Q2 net loss was $0.2 million versus a profit of $1.6 million in 2019. Clinical development includes progress on OPNT003 for opioid overdose and OPNT004 for cannabinoid overdose, while OPNT002's Phase 2 study is on hold due to COVID-19. Leadership changes include the appointment of Brian Gorman as General Counsel.
Opiant Pharmaceuticals (NASDAQ: OPNT) will release its second quarter 2020 financial results on August 6, 2020, after market close. A conference call and webcast hosted by the management team will follow at 4:30 p.m. ET. Interested parties can join the call by dialing 877-407-0792 for domestic calls or 201-689-8263 for international callers, using the conference ID 13706176. Opiant is known for developing medicines for addictions and drug overdose, including the NARCAN® Nasal Spray.
The U.S. District Court for New Jersey has ruled in favor of Teva Pharmaceuticals in a patent lawsuit concerning NARCAN® Nasal Spray. Opiant's partner, Emergent BioSolutions, plans to appeal this decision. CEO Roger Crystal expressed disappointment but emphasized NARCAN's critical role in fighting opioid overdoses and Opiant's commitment to developing new addiction treatments. The company maintains a strong financial position and a pipeline of potential medicines aimed at combatting addiction.
Opiant Pharmaceuticals (NASDAQ: OPNT) announced that CEO Dr. Roger Crystal will present a company overview at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 2:30 pm EDT. The event is virtual, and a live webcast will be available on Opiant's website. A replay of the presentation will be accessible for 90 days post-event.
Opiant is known for developing NARCAN® Nasal Spray and focuses on creating new medications for combating addictions and drug overdoses.
Opiant Pharmaceuticals announces a shift to a virtual format for its 2020 Annual Meeting due to COVID-19 health concerns. The meeting is scheduled for June 15, 2020, at 9:00 a.m. PDT, with shareholders able to participate via Zoom. Shareholders of record as of April 15, 2020, can vote electronically using their control number. The proxy card remains valid despite the format change. A list of eligible voters will be available starting June 5, 2020.
Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q1 2020 revenues of $4.3 million, driven primarily by NARCAN® royalties of $4.2 million, reflecting a 12% year-over-year increase.
The company anticipates full-year royalties of $26.2 million. Cash reserves stand at $32.2 million with no debt. The FDA removed the clinical hold on OPNT003, enabling progress towards a New Drug Application, now expected in early 2021.
However, recruitment for OPNT002 related to Alcohol Use Disorder is paused due to COVID-19.
FAQ
What is the market cap of Opiant Pharmaceuticals (OPNT)?
